SCHEDULE: Adage Capital Discloses 6.29% Stake in Centessa Pharma
Beneficial Ownership Disclosure
Adage Capital Management, L.P. and its principals have disclosed a 6.29% beneficial ownership stake in Centessa Pharmaceuticals plc, holding 8,403,000 ordinary shares.
Summary
- Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, collectively hold 8,403,000 ordinary shares of Centessa Pharmaceuticals plc.
- This ownership represents 6.29% of the company's outstanding ordinary shares.
- The shares are held through American Depositary Shares (ADSs), with each ADS representing one ordinary share.
- The beneficial ownership is held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- The percentage is calculated based on 133,618,774 ordinary shares outstanding as of May 1, 2025, as reported in Centessa's Form 10-Q for the quarter ended March 31, 2025.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects. The act of an institutional investor taking a significant stake can be interpreted positively by the market, but the filing itself is neutral.
Positives
- The disclosure of a significant stake by a reputable institutional investor like Adage Capital Management may be viewed positively by the market, signaling confidence in Centessa Pharmaceuticals plc.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of beneficial ownership by an institutional investor in a publicly traded pharmaceutical company. Such disclosures are common and provide transparency regarding significant stakes held by large funds.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which may influence market perception and trading activity.
Key Dates
| Date | Description |
|---|---|
| 05/01/2025 | Date as of which 133,618,774 Ordinary Shares were reported outstanding in Centessa's Form 10-Q. |
| 06/30/2025 | Date of event which required the filing of this statement. |
| 08/12/2025 | Date of filing of this Schedule 13G Amendment No. 1. |
Keywords
Centessa Pharmaceuticals, Adage Capital Management, Beneficial Ownership, Institutional Investor, SEC Filing, Schedule 13G, CNTA, Pharmaceuticals, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.